infections with fewer side effects than old compounds such as polymyxins. Avibactam is a diazabicyclooctane b-lactamase inhibitor that demonstrates excellent inhibitory properties against class A, class C and some class D b-lactamases (basically OXA-48). In contrast, it does not possess activity against most MBL-producing isolates. 1 Recently, ceftazidime/avibactam was approved for the treatment of patients with complicated intra-abdominal infections, complicated urinary tract infections and hospital-acquired pneumonia. 2 To reduce the development of drug-resistant bacteria and preserve the susceptibility of ceftazidime/avibactam, it should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. However, susceptibility testing of new drugs in routine laboratories is restricted to disc and/or gradient diffusion methodologies until its inclusion on commercial panels of susceptibility automated systems. According to a recent evaluation, ceftazidime/avibactam susceptibility testing using Etest and disc diffusion methods presented very major and major errors, respectively, compared to broth microdilution, and those tests should be interpreted cautiously in clinical practice. Research letters MALDI-TOF MS has been applied for the detection of carbapenems hydrolysis. 4 As susceptibility testing to ceftazidime/avibactam might be tricky, herein, we evaluated the performance of MALDI-TOF MS for rapid detection of ceftazidime/avibactam resistance by testing against 118 previous molecular characterized bacterial clinical isolates, including a range of different b-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa (Table 1) . 5, 6 In addition, 21 non-carbapenemase-producing isolates were also studied. Species identification was confirmed by MALDI-TOF MS (Biotyper 3.3 version; Bruker Daltonics, Bremen, Germany).
The MALDI-TOF MS hydrolysis assay was performed as previously reported with a few modifications. 7 The isolates were grown overnight on Mueller-Hinton agar plates (Oxoid TM , Basingstoke, UK) at 37 C. A 1 lL loop of each organism was inoculated into 100 lL of adjusted solution (20 mM Tris-HCl, pH 6.8) with ceftazidime/avibactam (0.20 and 0.05 g/L, respectively; Allergan, Pittsburgh, PA, USA). The reaction tubes were incubated at 37 C for 2 h. After the incubation period, each sample tube was centrifuged at 13 000 rpm for 2 min. One microlitre of the supernatant was spotted onto a MALDI-TOF MS target plate, followed by the addition of 1 lL of a-cyano-4-hydroxycinnamic acid matrix solution (10 g/L; diluted into 49.9% water, 50% acetonitrile and 0.1% trifluoroacetic acid). The mass spectrum was obtained using a Bruker Daltonics Microflex LT instrument, using the Flex Control 3.4 software in the m/z range of 400-600 Da. Avibactam restored the ceftazidime activity when the intact molecular mass peak of ceftzidime ([M ! H] ! 547.6 Da) and its pyridine-eliminated molecular mass peak (468.7 Da) were present. In contrast, a resistant phenotype was detected if a mass peak corresponding to pyridineeliminated hydrolysed form was observed (442.6 Da). 7 All isolates were submitted to ceftazidime/avibactam agar dilution susceptibility testing and confirmed by microdilution following the EUCAST guideline. 8 In addition, PCR and sequencing experiments were repeated and confirmed the presence of b-lactamase-encoding genes in isolates that showed discordant results (unexpected profile according to b-lactamase content). 6, 7 In this study, MALDI-TOF MS showed good results for the detection of a ceftazidime/avibactam category of susceptibility compared with those of antimicrobial susceptibility testing (94% agreement, 111 of 118) and molecular methods (97% agreement, 114 of 118) ( Table 1 ). Ceftazidime/avibactam was active against all class A and C b-lactamase-producing isolates tested by the MALDI-TOF MS assay. Carbapenem-hydrolysing class D b-lactamases produced by Acinetobacter spp. commonly do not recognize ceftazidime as a good substrate. In addition, it has been demonstrated that avibactam inhibits mainly OXA-48. In our study, ceftazidime/avibactam hydrolysis was not detected in OXA-48-, OXA-58-and OXA-72-producing isolates. Interestingly, an important reduction of ceftazidime MICs was observed for OXA-48-producing (from 16 to 1 mg/L) and OXA-58-producing (from 64 to 1 mg/L) isolates, when it was combined with avibactam. In contrast, both OXA-72-producing isolates showed high ceftazidime (MICs .64 mg/L) and ceftazidime/avibactam MICs (.64 mg/L), suggesting that other mechanisms of resistance such as hyperexpression of AdeABC systems are probably present in these isolates. 9 Interestingly, although avibactam inhibits GES variants, high ceftazidime/avibactam MICs were observed for isolates producing GES-1 and GES-16. These isolates also produce AmpC, so co-production of both class A and class C enzymes may impair the avibactam inhibitory activity. As expected, the majority of MBLproducing isolates (86.2%) were not inhibited by avibactam, because ceftazidime's intact molecule disappeared and the pyridineeliminated hydrolysed form was observed. Four IMP-1-producing isolates, two Proteus mirabilis and two Klebsiella pneumoniae, initially presented the intact molecular mass peak of ceftazidime detectable. However, ceftazidime hydrolysis was detected in these isolates, when the incubation period was extended to 4 h. These results are in accordance to the ceftazidime/avibactam susceptibility results. Previous studies have also reported in vivo activity of ceftazidime/avibactam against NDM-1-producing Enterobaceriaceae. 10, 11 Thus, the possible activity of ceftazidime/ avibactam against some MBL-producing Enterobacteriaceae should be confirmed by further studies.
As ceftazidime/avibactam has been prescribed for treating infections caused by MDR pathogens, which have few or no therapeutic alternatives, the early and accurate detection of ceftazidime/avibactam in vitro activity against those isolates would be useful to guide antimicrobial therapy. In this study, we applied a ceftazidime/avibactam assay for rapid detection of bacterial resistance to this combination. According to our findings, in addition to rapid microorganism identification, MALDI-TOF MS proved to be an excellent tool for screening ceftazidime/avibactam activity against Enterobacteriaceae isolates, particularly those that do not produce AmpC. To help clinicians to prescribe correctly the ceftazidime/avibactam, before the susceptibility testing results become available, routine laboratories could easily apply this MALDI-TOF MS assay. However, if an isolate shows both peaks corresponding to intact and hydrolysed molecules even after extending the incubation period to 4 h, a non-interpretable result must be reported, advising physicians to wait for final antimicrobial susceptibility results.
